Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Oncology Best Practice™: Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast Cancer

Oncology Best Practice™: Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast Cancer

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at or call (609) 325-4668

Oncology Best Practice™:
Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast Cancer
July 2017 - October 2017


The expanding arsenal of targeted therapies available for the treatment of patients with hormone receptor-positive metastatic breast cancer has allowed clinicians to hone management approaches and personalize care. While novel therapies and combinations—such as those using available oral CDK4/6 inhibitors—may benefit patients with breast cancer, they also add markedly to the complexity of care. The provision of expert guidance regarding the most appropriate and efficacious incorporation of CDK4/6 inhibitors into clinical management strategies for hormone-receptor positive, metastatic breast cancer can help the multidisciplinary team to apply state-of-the-art evidence to treatment practice. This, in turn, can help to optimize treatment efficacy and minimize potential adverse events for patients who may be candidates for these therapies.

This activity will bring renowned experts in the medical management of breast cancer directly to your practice sites to provide key insights and perspectives to breast cancer management teams. The practical case-based format of the program will focus on the incorporation of recent practice-changing evidence on CDK4/6 inhibitors by multidisciplinary teams in the context of managing real-world clinical scenarios. Importantly, the collegial atmosphere of Grand Rounds/Tumor Boards and small group settings will allow for open, fluid interaction with experts in the field, and participants will have the opportunity to have some of their most pressing patient case dilemmas addressed. Indeed, the patient will remain the focus of this activity via practical assessments of how individual characteristics impact diagnosis, clinical decision-making, and the provision of quality care.

Target Audience

This activity is directed toward medical oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pharmacists and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Educational Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Assess pharmacodynamics properties of cyclin-dependent kinase (CDK) 4/6 inhibition and how that is currently applied to the management of metastatic breast cancer
  2. Discuss pivotal trial results concerning the use of CDK4/6 inhibitors in the treatment of metastatic breast cancer
  3. Translate evolving evidence to apply CDK4/6 inhibitor approaches to the care of patients with metastatic breast cancer
  4. Identify strategies that can be integrated by multidisciplinary teams in institutions for the mitigation and management of predictable adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer


Joyce O’Shaughnessy, MD
Co-Director of Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX New York, NY

Become a Member

Forgot Password?
Calendar of Events
Filter By